Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VRN110755 |
| Synonyms | |
| Therapy Description |
VRN110755 is a brain-penetrant EGFR inhibitor with activity against EGFR mutations including C797S, which potentially inhibits growth of EGFR-mutant tumors (J Clin Oncol 2026 44: 16_suppl, 8623). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VRN110755 | VRN 110755|VRN-110755 | EGFR Inhibitor 4th gen 21 | VRN110755 is a brain-penetrant EGFR inhibitor with activity against EGFR mutations including C797S, which potentially inhibits growth of EGFR-mutant tumors (J Clin Oncol 2026 44: 16_suppl, 8623). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07699328 | Phase Ib/II | VRN110755 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (REACH-EGFR) | Recruiting | FRA | ESP | CAN | AUS | 6 |